Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and Interventions

English version České info

Background:
The global burden of sickle cell anaemia (SCA) is set to rise as a consequence of improved survival in high-prevalence low- and middle-income countries and population migration to higher-income countries. The host of quantitative evidence documenting these changes has not been assembled at the global level. The purpose of this study is to estimate trends in the future number of newborns with SCA and the number of lives that could be saved in under-five children with SCA by the implementation of different levels of health interventions.

Methods and Findings:
First, we calculated projected numbers of newborns with SCA for each 5-y interval between 2010 and 2050 by combining estimates of national SCA frequencies with projected demographic data. We then accounted for under-five mortality (U5m) projections and tested different levels of excess mortality for children with SCA, reflecting the benefits of implementing specific health interventions for under-five patients in 2015, to assess the number of lives that could be saved with appropriate health care services. The estimated number of newborns with SCA globally will increase from 305,800 (confidence interval [CI]: 238,400–398,800) in 2010 to 404,200 (CI: 242,500–657,600) in 2050. It is likely that Nigeria (2010: 91,000 newborns with SCA [CI: 77,900–106,100]; 2050: 140,800 [CI: 95,500–200,600]) and the Democratic Republic of the Congo (2010: 39,700 [CI: 32,600–48,800]; 2050: 44,700 [CI: 27,100–70,500]) will remain the countries most in need of policies for the prevention and management of SCA. We predict a decrease in the annual number of newborns with SCA in India (2010: 44,400 [CI: 33,700–59,100]; 2050: 33,900 [CI: 15,900–64,700]). The implementation of basic health interventions (e.g., prenatal diagnosis, penicillin prophylaxis, and vaccination) for SCA in 2015, leading to significant reductions in excess mortality among under-five children with SCA, could, by 2050, prolong the lives of 5,302,900 [CI: 3,174,800–6,699,100] newborns with SCA. Similarly, large-scale universal screening could save the lives of up to 9,806,000 (CI: 6,745,800–14,232,700) newborns with SCA globally, 85% (CI: 81%–88%) of whom will be born in sub-Saharan Africa. The study findings are limited by the uncertainty in the estimates and the assumptions around mortality reductions associated with interventions.

Conclusions:
Our quantitative approach confirms that the global burden of SCA is increasing, and highlights the need to develop specific national policies for appropriate public health planning, particularly in low- and middle-income countries. Further empirical collaborative epidemiological studies are vital to assess current and future health care needs, especially in Nigeria, the Democratic Republic of the Congo, and India.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and Interventions. PLoS Med 10(7): e32767. doi:10.1371/journal.pmed.1001484
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001484

Souhrn

Zdroje

1. KomatsuR, KorenrompEL, Low-BeerD, WattC, DyeC, et al. (2010) Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis 10: 109.

2. KatzI, KomatsuR, Low-BeerD, AtunR (2011) Scaling up towards international targets for AIDS, tuberculosis, and malaria: contribution of global fund-supported programs in 2011–2015. PLoS ONE 6: e17166 doi:10.1371/journal.pone.0017166

3. Christianson AC, Howson CP, Modell B (2006) The March of Dimes global report on birth defects: the hidden toll of dying and disabled children. White Plains (New York): March of Dimes.

4. Howson CP, Christianson AC, Modell B (2008) Controlling birth defects: reducing the hidden toll of dying and disabled children in lower-income countries. Washington (District of Columbia): Disease Control Priorities Project.

5. WeatherallD (2011) The inherited disorders of haemoglobin: an increasingly neglected global health burden. Indian J Med Res 134: 493–497.

6. WeatherallDJ (2010) The inherited diseases of hemoglobin are an emerging global health burden. Blood 115: 4331–4336.

7. ReesDC, WilliamsTN, GladwinMT (2010) Sickle-cell disease. Lancet 376: 2018–2031.

8. ModellB, DarlisonM (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86: 480–487.

9. PielFB, PatilAP, HowesRE, NyangiriOA, GethingPW, et al. (2010) Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun 1: 104.

10. GrosseSD, OdameI, AtrashHK, AmendahDD, PielFB, et al. (2011) Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 41: S398–S405.

11. WilliamsTN, UyogaS, MachariaA, NdilaC, McAuleyCF, et al. (2009) Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet 374: 1364–1370.

12. ScottJA, BerkleyJA, MwangiI, OcholaL, UyogaS, et al. (2011) Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 378: 1316–1323.

13. RajaratnamJK, MarcusJR, FlaxmanAD, WangH, Levin-RectorA, et al. (2010) Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970–2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet 375: 1988–2008.

14. LiuL, JohnsonHL, CousensS, PerinJ, ScottS, et al. (2012) Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379: 2151–2161.

15. FotsoJC, EzehAC, MadiseNJ, CieraJ (2007) Progress towards the child mortality millennium development goal in urban sub-Saharan Africa: the dynamics of population growth, immunization, and access to clean water. BMC Public Health 7: 218.

16. SayemAM, NuryAT, HossainMD (2011) Achieving the millennium development goal for under-five mortality in Bangladesh: current status and lessons for issues and challenges for further improvements. J Health Popul Nutr 29: 92–102.

17. MasseyDS, ArangoJ, HugoG, KouaouciA, PellegrinoA, et al. (1993) Theories of international migration: a review and appraisal. Popul Dev Rev 19: 431–466.

18. World Health Organization (2006) Fifty-ninth World Health Assembly: resolutions and decisions, annexes. WHA59/2006/REC/1. Geneva: World Health Organization.

19. MurrayCJL, EzzatiM, FlaxmanAD, LimS, LozanoR, et al. (2012) GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiology. Lancet 380: 2055–2058.

20. MyersMF, RogersDJ, CoxJ, FlahaultA, HaySI (2000) Forecasting disease risk for increased epidemic preparedness in public health. Adv Parasitol 47: 309–330.

21. PielFB, PatilAP, HowesRE, NyangiriOA, GethingPW, et al. (2013) Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 380: 142–151.

22. United Nations Population Division (2010) World population prospects, the 2010 revision. New York: United Nations Population Division. Available: http://esa.un.org/unpd/wpp/index.htm. Accessed 12 June 2013.

23. LivingstoneFB (1964) Aspects of the population dynamics of the abnormal hemoglobin and glucose-6-phosphate dehydrogenase deficiency genes. Am J Hum Genet 16: 435–450.

24. Bodmer WF, Cavalli-Sforza LL (1976) Genetics, evolution, and man. San Francisco: W. H. Freeman. 782 p.

25. HanchardNA, HambletonI, HardingRM, McKenzieCA (2005) The frequency of the sickle allele in Jamaica has not declined over the last 22 years. Br J Haematol 130: 939–942.

26. YanniE, GrosseSD, YangQ, OlneyRS (2009) Trends in pediatric sickle cell disease-related mortality in the United States, 1983–2002. J Pediatr 154: 541–545.

27. VichinskyE, HurstD, EarlesA, KlemanK, LubinB (1988) Newborn screening for sickle cell disease: effect on mortality. Pediatrics 81: 749–755.

28. LeeA, ThomasP, CupidoreL, SerjeantB, SerjeantG (1995) Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ 311: 1600–1602.

29. KingL, FraserR, ForbesM, GrindleyM, AliS, et al. (2007) Newborn sickle cell disease screening: the Jamaican experience (1995–2006). J Med Screen 14: 117–122.

30. FlemingAF, StoreyJ, MolineauxL, IrokoEA, AttaiED (1979) Abnormal haemoglobins in the Sudan savanna of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Ann Trop Med Parasitol 73: 161–172.

31. PlattOS, BrambillaDJ, RosseWF, MilnerPF, CastroO, et al. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. New Engl J Med 330: 1639–1644.

32. SimporeJ, PignatelliS, BarlatiS, MusumeciS (2002) Modification in the frequency of Hb C and Hb S in Burkina Faso: an influence of migratory fluxes and improvement of patient health care. Hemoglobin 26: 113–120.

33. QuinnCT, RogersZR, BuchananGR (2004) Survival of children with sickle cell disease. Blood 103: 4023–4027.

34. QuinnCT, RogersZR, McCavitTL, BuchananGR (2010) Improved survival of children and adolescents with sickle cell disease. Blood 115: 3447–3452.

35. TelferP, CoenP, ChakravortyS, WilkeyO, EvansJ, et al. (2007) Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 92: 905–912.

36. SaaryMJ (2008) Radar plots: a useful way for presenting multivariate health care data. J Clin Epidemiol 61: 311–317.

37. WeatherallDJ (2011) The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol 154: 736–744.

38. BrownsonRC, FieldingJE, MaylahnCM (2009) Evidence-based public health: a fundamental concept for public health practice. Annu Rev Public Health 30: 175–201.

39. Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P (2006) Inherited disorders of hemoglobin. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, et al.., editors. Disease control priorities in developing countries, 2nd edition. New York: Oxford University Press. pp. 663–680.

40. Weatherall DJ, Clegg JB (2001) The thalassaemia syndromes. Oxford: Blackwell Science. 846 p.

41. de SilvaS, FisherCA, PremawardhenaA, LamabadusuriyaSP, PetoTEA, et al. (2000) Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Lancet 355: 786–791.

42. PanepintoJA, MagidD, RewersMJ, LanePA (2000) Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 136: 201–208.

43. GrosseSD, OlneyRS, BailyMA (2005) The cost effectiveness of universal versus selective newborn screening for sickle cell disease in the US and the UK: a critique. Appl Health Econ Health Policy 4: 239–247.

44. OdunvbunME, OkoloAA, RahimyCM (2008) Newborn screening for sickle cell disease in a Nigerian hospital. Public Health 122: 1111–1116.

45. Adeola AnimasahunB, NwodoU, NjokanmaOF (2012) Prenatal screening for sickle cell anemia: awareness among health professionals and medical students at the Lagos University Teaching Hospital and the concept of prevention by termination. J Pediatr Hematol Oncol 34: 252–256.

46. Akinyanju O (2010) The national burden of sickle cell disorder and the way forward. Lagos: Sickle Cell Foundation Nigeria.

47. TshiloloL, KafandoE, SawadogoM, CottonF, VertongenF, et al. (2008) Neonatal screening and clinical care programmes for sickle cell disorders in sub-Saharan Africa: lessons from pilot studies. Public Health 122: 933–941.

48. AgasaB, BosungaK, OparaA, TshilumbaK, DupontE, et al. (2010) Prevalence of sickle cell disease in a northeastern region of the Democratic Republic of Congo: what impact on transfusion policy? Transfus Med 20: 62–65.

49. TshiloloL, AissiLM, LukusaD, KinsiamaC, WembonyamaS, et al. (2009) Neonatal screening for sickle cell anaemia in the Democratic Republic of the Congo: experience from a pioneer project on 31 204 newborns. J Clin Pathol 62: 35–38.

50. PatraPK, ChauhanVS, KhodiarPK, DallaAR, SerjeantGR (2011) Screening for the sickle cell gene in Chhattisgarh state, India: an approach to a major public health problem. J Community Genet 2: 147–151.

51. DasR (2012) Micro mapping the frequencies of beta thalassemia and sickle cell anemia in India: a way forward to plan control strategies. Indian J Hum Genet 18: 148–149.

52. MohantyD, ColahRB, GorakshakarAC, PatelRZ, MasterDC, et al. (2013) Prevalence of beta-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet 4: 33–42.

53. AlswaidiFM, MemishZA, O'BrienSJ, Al-HamdanNA, Al-EnzyFM, et al. (2012) At-risk marriages after compulsory premarital testing and counseling for beta-thalassemia and sickle cell disease in Saudi Arabia, 2005–2006. J Genet Couns 21: 243–255.

54. CaoA, GalanelloR, RosatelliMC (1998) Prenatal diagnosis and screening of the haemoglobinopathies. Baillieres Clin Haematol 11: 215–238.

55. LoukopoulosD (2011) Haemoglobinopathies in Greece: prevention programme over the past 35 years. Indian J Med Res 134: 572–576.

56. GastonMH, VerterJI, WoodsG, PegelowC, KelleherJ, et al. (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. New Engl J Med 314: 1593–1599.

57. Serjeant GR (2001) Geographic hetereogeneity of sickle cell disease. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of hemoglobin, 1st edition. Cambridge: Cambridge University Press.

58. JainD, ItaliaK, SarathiV, GhoshandK, ColahR (2012) Sickle cell disease from central India: a retrospective analysis. Indian Pediatr 49: 911–913.

59. KulozikAE, WainscoatJS, SerjeantGR, KarBC, Al-AwamyB, et al. (1986) Geographical survey of beta S-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hum Genet 39: 239–244.

60. KulozikAE, KarBC, SatapathyRK, SerjeantBE, SerjeantGR, et al. (1987) Fetal hemoglobin levels and beta (s) globin haplotypes in an Indian populations with sickle cell disease. Blood 69: 1742–1746.

61. BittlesA (2001) Consanguinity and its relevance to clinical genetics. Clin Genet 60: 89–98.

62. BittlesAH (2002) Endogamy, consanguinity and community genetics. J Genet 81: 91–98.

63. Organisation for Economic Co-operation and Development (2013) International migration database [database]. Paris: Organisation for Economic Co-operation and Development.

64. TatemAJ, QiuY, SmithDL, SabotO, AliAS, et al. (2009) The use of mobile phone data for the estimation of the travel patterns and imported Plasmodium falciparum rates among Zanzibar residents. Malar J 8: 287.

65. LuX, BengtssonL, HolmeP (2012) Predictability of population displacement after the 2010 Haiti earthquake. Proc Natl Acad Sci U S A 109: 11576–11581.

66. WeatherallDJ, CleggJB (2001) Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 79: 704–712.